Clinical trials: ITP - Immune Thrombocytopenia
Primary Immune Thrombocytopenia (ITP)
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune disease mainly mediated by autoreactive B cells and the presence of pathogenic anti-platelet auto-antibodies that enhance platelet destruction and impair platelet production.
- Trial name
- RITUX-PLUS 2 (NCT05338190)
- Testing
- Combination of Rituximab with subcutaneous belimumab
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP), with a 6-month Safety…
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura
- Trial name
- NCT00415532
- Testing
- Medical Standard of Care for ITP, Romiplostim
- Volunteers
- 234 people
- Sponsor
- Amgen
ITP, Immune Thrombocytopenia
Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia
Single-arm, open-label, single-center study to evaluate the efficacy and safety of baricitinib for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).
- Trial name
- BAITP (NCT05446831)
- Testing
- Baricitinib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia, ITP
Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP
Multicenter retrospective and prospective observational study based on the collection of sequential anonymized data from principal Italian ITP centers, to describe the clinical course of ITP patients becoming infected by…
- Conditions
- Immune Thrombocytopenia, ITP, Covid19, ITP Secondary to Infection
- Trial name
- NCT04735588
- Where
- 8 sites in Italy
- Volunteers
- 140 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
ITP, Immune Thrombocytopenia
The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of combination of iguratimod and danazol versus danazol for the treatment of adults with steroid-resistant/ relapse immune thrombocytopenia (ITP).
- Trial name
- NCT05281068
- Testing
- Iguratimod, Danazol
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia, ITP
Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia
This study developed the first prediction model for risk of critical ITP bleeds for ITP inpatients using a novel machine learning algorithm.
- Trial name
- NCT05116423
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE)
Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)
The aim of this proposal is to test if anti-BAFF antibody can restore a normal threshold of tolerance in patients in two auto-immune diseases along the RITUX-PLUS study in immune thrombocytopenia, and along the Believe study in…
- Trial name
- ITP&SLE (NCT03975361)
- Testing
- Bliss-Believe
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune Thrombocytopenia (ITP)
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
The primary objective of this study was to assess the efficacy of 3 dose levels of lusutrombopag (0.5 mg, 0.75 mg, and 1.0 mg) and placebo on platelet count.
- Trial name
- NCT01054443
- Testing
- Lusutrombopag
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Shionogi
ITP, Immune Thrombocytopenia
The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of Combination of High-dose Dexamethasone and Tacrolimus versus High-dose Dexamethasone for the first-line treatment of adults with primary immune…
- Trial name
- NCT04747080
- Testing
- Dexamethasone, Tacrolimus
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
Primary Immune Thrombocytopenia (ITP)
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.
- Trial name
- ADVANCE2 (NCT04274452)
- Testing
- efgartigimod
- Sponsor
- argenx
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
This is an extension study designed to assess the safety and durability of platelet count increases with romiplostim treatment of thrombocytopenic patients with immune (Idiopathic) thrombocytopenia purpura.
- Trial name
- NCT01071954
- Testing
- Romiplostim
- Where
- 31 sites in United States, Australia and 2 more
- Volunteers
- 66 people
- Sponsor
- Amgen
Primary Immune Thrombocytopenia (ITP)
Study of Immune Thrombocytopenia Pathogenesis:
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells.
- Trial name
- PTI PARI (NCT02042560)
- Testing
- Blood samples, Spleen samples
- Where
- 3 sites in France
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Adult Immune Thrombocytopenia (ITP), Dapsone
Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia
Due to its expected efficacy based on the retrospective data available in ITP, its relatively good safety profile and its very low cost , dapsone could be a good steroid-sparing second-line option for adults with ITP.
- Trial name
- DAPS-ITP (NCT02627417)
- Testing
- Dapsone (Disulone®), Prednisone (Cortancyl®) alone followed by monitoring and "standard of care", Prednisone (Cortancyl®)
- Where
- France
- Volunteers
- 216 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
The purpose of this study is to evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in pediatric patients with Immune thrombocytopenia purpura (ITP) as measured by durable platelet response.
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
- Trial name
- NCT01444417
- Testing
- Romiplostim
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 62 people
- Sponsor
- Amgen
Immune Thrombocytopenia (ITP)
Autoantibody Specificity and Response to IVIG in ITP
The objective of this human study was to evaluate the association between the specificity of anti-platelet autoantibodies and response to IVIG treatment.
- Trial name
- NCT01666795
- Where
- China
- Volunteers
- 672 people
- Sponsor
- Shandong University
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
The purpose of this study is to evaluate the safety and tolerability of romiplostim (AMG 531) in the treatment of thrombocytopenia in pediatric subjects with chronic ITP.
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
- Trial name
- NCT00515203
- Testing
- AMG 531
- Volunteers
- 22 people
- Sponsor
- Amgen
Immune Thrombocytopenia (ITP)
Rituximab as Second Line Treatment for ITP
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized thrombocytopenia. Splenectomy is the standard treatment for patients who fails the first-line treatment: corticosteroid.
- Trial name
- NCT00344149
- Testing
- Rituximab (Mabthera)
- Where
- Norway
- Volunteers
- 112 people
- Sponsor
- Ostfold Hospital Trust
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
This is a multi-center prospective observational descriptive study complemented by a retrospective chart review. Patients diagnosed with ITP and currently treated for ITP by a hematologist or hematologist-oncologist will be…
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura
- Trial name
- NCT00454857
- Testing
- Retrospective Chart Review, Patient-reported Outcome Questionnaires, Physician Survey
- Volunteers
- 326 people
- Sponsor
- Amgen